1-20 of 38
glucagon-like peptide-1 agonists
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A1C: Episode 3

Nay Linn Aung
Journal: Clinical Diabetes
Clin Diabetes 2024;42(3):448–451
https://doi.org/10.2337/cd24-0038
Published: 02 May 2024
View article titled, A1C: Episode 3
Open the PDF for A1C: Episode 3 in another window
Journal Articles

Timely News and Notes for Primary Care Providers from the American Diabetes Association

Max Bingham, PhD
Journal: Clinical Diabetes
Clin Diabetes 2024;42(1):5–9
https://doi.org/10.2337/cd24-dp01
Published: 15 January 2024
View article titled, Timely News and Notes for Primary Care Providers from the American Diabetes Association
Open the PDF for Timely News and Notes for Primary Care Providers from the American Diabetes Association in another window
Journal Articles

Accidental Once-Daily Use of Dulaglutide: A Case Report

Hannah E. Moore, Viva Zaya, Carly V. Burns, Helen D. Berlie
Journal: Clinical Diabetes
Clin Diabetes 2024;42(3):454–457
https://doi.org/10.2337/cd23-0035
Published: 12 January 2024
View article titled, Accidental Once-Daily Use of Dulaglutide: A Case Report
Open the PDF for Accidental Once-Daily Use of Dulaglutide: A Case Report in another window
Journal Articles

Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion

Nicole M. Ehrhardt, Vanita R. Aroda, Rodolfo J. Galindo, Anne L. Peters, Jay H. Shubrook
Journal: Clinical Diabetes
Clin Diabetes 2024;42(2):341–350
https://doi.org/10.2337/cd23-0047
Published: 05 December 2023
View article titled, Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion
Open the PDF for Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion in another window
Journal Articles

Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study

Aseel Yaseen, Sharon W. Lahiri
Journal: Clinical Diabetes
Clin Diabetes 2023;41(4):490–501
https://doi.org/10.2337/cd22-0100
Published: 14 April 2023
View article titled, Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study
Open the PDF for Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study in another window
Journal Articles

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Heather P. Whitley, Jennifer M. Trujillo, Joshua J. Neumiller
Journal: Clinical Diabetes
Clin Diabetes 2023;41(3):467–473
https://doi.org/10.2337/cd23-0023
Published: 07 April 2023
View article titled, Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
Open the PDF for Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages in another window
Journal Articles

Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin

Alexis V. Fanshier, Brianne K. Crews, Madison C. Garrett, Jeremy L. Johnson
Journal: Clinical Diabetes
Clin Diabetes 2023;41(3):367–377
https://doi.org/10.2337/cd22-0060
Published: 02 March 2023
View article titled, Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin
Open the PDF for Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin in another window
Journal Articles

Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?

Aaron King, Eden M. Miller
Journal: Clinical Diabetes
Clin Diabetes 2023;41(2):226–238
https://doi.org/10.2337/cd22-0027
Published: 03 November 2022
View article titled, Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
Open the PDF for Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low? in another window
Journal Articles

A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist

Muralikrishna Gangadharan Komala, Jasveen Renthawa
Journal: Clinical Diabetes
Clin Diabetes 2022;40(4):508–510
https://doi.org/10.2337/cd21-0142
Published: 14 October 2022
View article titled, A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist
Open the PDF for A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist in another window
Journal Articles

Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy

Kaylan N. Davis, Abigail E. Hines, Margaret C. Schaefer, Kristina W. Naseman
Journal: Clinical Diabetes
Clin Diabetes 2022;40(3):305–311
https://doi.org/10.2337/cd21-0090
Published: 01 July 2022
View article titled, Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy
Open the PDF for Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy in another window
Journal Articles

Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary

John Anderson, James R. Gavin, III, Davida F. Kruger, Eden Miller
Journal: Clinical Diabetes
Clin Diabetes 2022;40(3):265–269
https://doi.org/10.2337/cd22-0020
Published: 01 July 2022
View article titled, Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary
Open the PDF for Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary in another window
Journal Articles

How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?

Joseph Tibaldi, Max E. Mercado, Jodi Strong
Journal: Clinical Diabetes
Clin Diabetes 2020;38(4):339–347
https://doi.org/10.2337/cd20-0014
Published: 01 October 2020
View article titled, How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
Open the PDF for How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice? in another window
Journal Articles

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Jaime P. Almandoz, Ildiko Lingvay, Javier Morales, Carlos Campos
Journal: Clinical Diabetes
Clin Diabetes 2020;38(4):390–402
https://doi.org/10.2337/cd19-0100
Published: 01 October 2020
View article titled, Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Open the PDF for Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance in another window
Journal Articles

Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes

Iakovos Avramidis, Athanasia Apsemidou, Antigoni Z. Lalia, Nikolaos Petridis, Euangelos Tourtouras, Georgios Kalopitas, Georgios Pilianidis
Journal: Clinical Diabetes
Clin Diabetes 2020;38(3):248–255
https://doi.org/10.2337/cd19-0090
Published: 01 July 2020
View article titled, Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes
Open the PDF for Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes in another window
Journal Articles

Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients

Ian Blumer, Lucia M. Novak, Steven Edelman, Tricia Santos Cavaiola
Journal: Clinical Diabetes
Clin Diabetes 2019;37(4):386–390
https://doi.org/10.2337/cd18-0102
Published: 01 October 2019
View article titled, Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients
Open the PDF for Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients in another window
Journal Articles

Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?

Robert H. Eckel, Azeez Farooki, Robert R. Henry, Gary G. Koch, Lawrence A. Leiter
Journal: Clinical Diabetes
Clin Diabetes 2019;37(4):316–337
https://doi.org/10.2337/cd19-0001
Published: 01 October 2019
View article titled, Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Open the PDF for Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? in another window
Journal Articles

Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease

Kenneth S. Hershon, Barbara R. Hirsch, Ola Odugbesan
Journal: Clinical Diabetes
Clin Diabetes 2019;37(3):250–259
https://doi.org/10.2337/cd18-0040
Published: 01 July 2019
View article titled, Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Open the PDF for Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease in another window
Journal Articles

Nonglycemic Outcomes of Antidiabetic Medications

Christopher Morse, David Sze, Dhiren Patel, Jennifer Goldman
Journal: Clinical Diabetes
Clin Diabetes 2019;37(2):131–141
https://doi.org/10.2337/cd18-0015
Published: 01 April 2019
View article titled, Nonglycemic Outcomes of Antidiabetic Medications
Open the PDF for Nonglycemic Outcomes of Antidiabetic Medications in another window
Journal Articles

Oral Semaglutide

Vinh Bui, Joshua J. Neumiller
Journal: Clinical Diabetes
Clin Diabetes 2018;36(4):327–329
https://doi.org/10.2337/cd18-0034
Published: 01 October 2018
View article titled, Oral Semaglutide
Open the PDF for Oral Semaglutide in another window
Journal Articles

ITCA 650

Taylor Bertsch, Kimberly McKeirnan
Journal: Clinical Diabetes
Clin Diabetes 2018;36(3):265–267
https://doi.org/10.2337/cd18-0039
Published: 01 July 2018
View article titled, ITCA 650
Open the PDF for ITCA 650 in another window